Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03351322
Other study ID # ENERGI-F701-01
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 23, 2018
Est. completion date December 26, 2019

Study information

Verified date November 2020
Source Energenesis Biomedical Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate the efficacy and safety of ENERGI-F701 Solution in female subjects with hair loss.


Recruitment information / eligibility

Status Completed
Enrollment 67
Est. completion date December 26, 2019
Est. primary completion date November 29, 2019
Accepts healthy volunteers No
Gender Female
Age group 20 Years and older
Eligibility Inclusion Criteria: 1. Female, aged at least 20 years old 2. With hair loss over 100 hairs/day 3. Willing to maintain the same hair style, color, shampoo and hair products used, and approximate hair length starting from signing ICF and throughout the study 4. The subject of childbearing potential must show a negative urine or serum pregnancy test at Screening Visit 5. Have signed the written informed consent form Exclusion Criteria: Any subject meeting any of the exclusion criteria will be excluded from study participation. 1. With alopecia areata or cicatricial alopecia 2. With other scalp or hair disorders 3. With prior hair transplant 4. Use wigs or hair weaves 5. Plan to use any other concomitant therapy to treat hair loss, regrowth or volume during the study 6. Have taken any topical or systemic prescription of OTC medications for treating hair loss, hair regrowth and/or hair volume 7. Have used medications known to cause hair thinning, such as Coumadin and anti-depressants/anti-psychotics 8. Have received chemotherapy/cytotoxic agents as well as radiation/laser/surgical therapy of the scalp 9. Have initiated or terminated the use of hormones for birth control or hormone replacement therapy within 6 months. Subject will also be excluded from the study if she plans to initiate or terminate the use of hormones for birth control or hormone replacement therapy during the study. 10. With known or suspected hypersensitivity any ingredients of study product and active control 11. Any hematologic abnormalities. 12. Any serum chemistry abnormalities. 13. Pregnant, lactating, or premenopausal with childbearing potential but not adopting at least one form of birth control. 14. Enrollment in any investigational drug trial 15. With any condition judged by the investigator that entering the trial may be detrimental to the subject

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ENERGI-F701
ENERGI-F701 are applied for treatment of hair loss.
Regaine
Regaine are applied for treatment of hair loss.

Locations

Country Name City State
Taiwan Taipei Veterans General Hospital Taipei

Sponsors (2)

Lead Sponsor Collaborator
Energenesis Biomedical Co., Ltd. A2 Healthcare Taiwan Corporation

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary The amount of hair loss Change of the amount of hair loss at Week 12 from baseline.(hair loss is defined as the collection of hairs after combing at the study site) Week 12
Secondary The amount of hair loss at each post-treatment visit Week 2, 4, 6, 8, 10
Secondary The thickness and density of hair Change of hair thickness and density measured by phototrichogram at each post-treatment visit Week 2, 4, 6, 8, 10, 12
Secondary Investigator assessment at each post-treatment visit The hair loss will be assessed by the investigator using Investigator Photographic Assessment Questionnaire (IPAQ).The change from Baseline in hair growth will be assessed using the following 7-point scale: -3 = greatly decreased, -2 = moderately decreased, -1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased. Week 2, 4, 6, 8, 10, 12
Secondary The hair wash/shed hair count at each post-treatment visit Subjects will collect hairs full day, including after combing and hair-washing. Subjects should turn in these hair collections at each visit. The results will be averaged weekly. Week 2, 4, 6, 8, 10, 12
Secondary The subject satisfaction Subject satisfaction evaluated by Women's Androgenic Alopecia Quality of Life Questionnaire (WAA-QOL) at each post-treatment visit from baseline. WAA-QOL is a sixteen-question questionnaire to evaluate subjects' quality of life influenced by hair loss. Each question will be assessed using the following 7-point scale: 0 = not at all, 1 = a little bit, 2 = somewhat, 3 = a good bit, 4 = quite a bit , 5 = very much, 6 = extremely. Week 2, 4, 6, 8, 10, 12
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04953416 - Fractional Non-ablative Laser for the Treatment of Hair Loss N/A
Completed NCT01929330 - Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers Phase 1
Recruiting NCT05213936 - Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color N/A
Completed NCT02919735 - Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN) Phase 2
Recruiting NCT02591823 - Hair Fall in Patients on Low Dose Methotrexate N/A
Enrolling by invitation NCT01651689 - Hair Counts From Vertical and Horizontal Sections of Scalp Biopsy SPecimens in Thai Population With Alopecia N/A
Completed NCT01189279 - Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia Phase 1
Recruiting NCT01111981 - Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia Phase 4
Terminated NCT01385839 - Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata N/A
Active, not recruiting NCT03382184 - Fractional Photothermolysis for Hair Follicle Induction Early Phase 1
Not yet recruiting NCT05544448 - In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases N/A
Completed NCT03689452 - The Effect of Platelet Rich Plasma on Non-scarring Alopecia N/A
Completed NCT06409650 - To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia Phase 2
Recruiting NCT00801086 - Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain Phase 2
Completed NCT06095739 - Study to Investigate the Effectiveness of a Topical Cosmetic Formulation DA-OTC-002 N/A
Completed NCT05587699 - The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A Phase 1
Terminated NCT02935569 - Compression Headband Use to Prevent Hair Loss During Whole Brain Radiotherapy N/A
Not yet recruiting NCT01557491 - Hair Regrowth After Bicoronal Incision N/A
Completed NCT01590238 - Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM) Phase 3
Completed NCT00515762 - Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling Phase 2